Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
H101, Tislelizumab, and Lenvatinib for Advanced Pancreatic Cancer
NCT05303090Phase 1Completed
- Sponsor
- Fudan University
- Start
- Mar 2022
- Primary completion
- Apr 2024
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label trial of Oncorine in pancreatic ductal adenocarcinoma (PDAC), sponsored by Fudan University. Primary endpoint: Dose Limiting Toxicities at 28 days. Started Mar 2022; status: completed.
02
Drugs
Oncorine
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05303090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05303090.